Modulators of the Sphingosine 1-phosphate receptor 1.

@article{Urbano2013ModulatorsOT,
  title={Modulators of the Sphingosine 1-phosphate receptor 1.},
  author={Mariangela Urbano and Miguel Guerrero and Hugh Rosen and Edward Roberts},
  journal={Bioorganic \& medicinal chemistry letters},
  year={2013},
  volume={23 23},
  pages={
          6377-89
        }
}
The Sphingosine 1-phosphate receptor (S1P-R) signaling system has proven to be of biological and medical importance in autoimmune settings. S1P1-R is a validated drug target for multiple sclerosis (MS) for which FTY720 (Fingolimod), a S1P1,3-5-R pan-agonist, was recently approved as the first orally active drug for the treatment of relapsing-remitting MS. Transient bradycardia and long half-life are the FTY720 critical pitfalls. This review provides the latest advances on next-generation S1P1-R… Expand
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
TLDR
In vitro and in vivo tests proved the multistep syntheses of various fluorine substituted 12-aryl analogues of the drug fingolimod and a seven-steps route to 2-amino-17,17-difluoro-2-(hydroxymethyl)heptadecan-1-ol as potent S1P1 receptor agonists. Expand
The organization of the sphingosine 1-phosphate signaling system.
TLDR
Innovative genetic and chemical approaches now provide a more detailed molecular understanding of a regulated lysophospholipid ligand with a variety of autocrine, paracrine, and systemic effects in physiology and pathology, based upon selective interactions with a high affinity and selective evolutionary cluster of G-protein-coupled receptors. Expand
Structural biology of the S1P1 receptor.
  • M. Hanson, R. Peach
  • Medicine, Biology
  • Current topics in microbiology and immunology
  • 2014
TLDR
Key structural features for the S1P1 receptor are reviewed and the potential binding modes of additional pharmacologically active agents against the receptor will be analyzed in an effort to better understand the structural basis of important receptor-ligand interactions. Expand
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
TLDR
Results from the EXPAND study of siponimod suggest a potential role for S1PR modulators in secondary progressive MS, and data from phase II trials and early results from phase III studies have been promising and will be presented in this review. Expand
Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015)
TLDR
Clinical and preclinical studies of second generation S1P1-R agonists have been generating interesting results and may finally provide pharmacological agents with improved therapeutic profile than FTY720, particularly in terms of cardiovascular and pulmonary liabilities. Expand
Synthesis of fluorinated agonist of sphingosine-1-phosphate receptor 1.
TLDR
A fluorinated analogue of S1P receptor agonist has been synthesized by utilizing a ring opening reaction of oxacycles by a lithiated difluoromethylphosphonate anion as the key reaction. Expand
Design and synthesis of analogues of the sphingosine-1-phosphate receptor 1 agonist IMMH001 with improved phosphorylation rate in human blood.
TLDR
Head-piece-modified analogues of IMMH001 showed higher phosphorylation rates in human blood than the parent compound and may have better therapeutic potential, indicated that the pro-R hydroxymethyl in the head-pieces-moiety of IM MH001 prevents thePro-S hydroxcyethyl from being phosphorylated by the kinase and ATP. Expand
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
TLDR
In conclusion, S1P modulators represent a novel and promising therapeutic strategy for immune-mediated diseases and concerns relating to S1PR modulators are leukopenia, anemia, transaminase elevation, macular edema, teratogenicity, pulmonary disorders, infections, and cardiovascular events. Expand
Synthesis and evaluation of fluorinated fingolimod (FTY720) analogues for sphingosine-1-phosphate receptor molecular imaging by positron emission tomography.
TLDR
This work presents the synthesis of various fluorinated structural analogues of FTY720, their in vitro and in vivo biological testing, and their development and application as radiotracers for the study of S1PR biodistribution and imaging in mice using small-animal positron emission tomography (PET). Expand
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
TLDR
Long-term safety, tolerability, and persistence profiles of fingolimod should reassure clinicians that sphingosine-1-phosphate receptor modulators are likely to be suitable for the long-term treatment of multiple sclerosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
TLDR
The immunomodulatory potential of BAF312 and the S1P receptor‐mediated effects on heart rate are characterized using preclinical and human data. Expand
Sphingosine 1-phosphate receptor signaling.
TLDR
The sphingosine 1-phosphate (S1P) receptor signaling system, based in part on receptor subtype-selectivity and on differential attenuation of deleterious signals, now appears to be on the cusp of meaningful therapy for multiple sclerosis. Expand
The structure and function of the S1P1 receptor.
TLDR
The structure and function of S1PR1 is outlined, highlighting the key residues involved in receptor activation, signaling, transmembrane interactions, ligand binding, post-translational modification, and protein-protein interactions. Expand
Sphingosine 1-phosphate receptor agonists: a patent review (2010 – 2012)
TLDR
This review provides the patent literature from 2010 to date on S1P-R agonist molecules and their relevant biological properties and reveals a discrete number of reviewed molecules with a promising clinical outlook in transplantation, inflammation, cancer and autoimmune settings. Expand
A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
TLDR
NIBR-0213 showed comparable therapeutic efficacy to fingolimod in experimental autoimmune encephalomyelitis (EAE), a model of human MS, providing convincing evidence that S1P(1) antagonists are effective in EAE. Expand
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
TLDR
Three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compound potency on S 1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia versus brady Cardia and hypertension was consistent with affinity for S1 p1 relative to S1p3; and toxicity, brady cardia, and hypertension were absent in S1 P3-/- mice. Expand
Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists.
TLDR
The optimized and S1P(3) selective S1p(1) agonist 9f induced peripheral blood lymphocyte reduction in vivo and has an excellent efficacy in mouse experimental autoimmune encephalomyelitis (EAE). Expand
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
TLDR
High-throughput screening campaign revealed hit 1 for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chemical scaffold, which led to the discovery of proline derivatives 37 (XL541) and 38 which had similar efficacy as the first generation analogues at significantly lower doses. Expand
Structural and functional characteristics of S1P receptors
The sphingosine‐1‐phosphate (S1P) family of G protein‐coupled receptors (GPCR) regulates essential cellular processes such as proliferation, migration, cytoskeletal organization, adherens junctionExpand
An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
TLDR
It is demonstrated that clinically useful immunomodulation mediated by the S1P(1) receptor can be achieved with an S1p( 1) antagonist generated in vivo after oral administration of its prodrug. Expand
...
1
2
3
4
5
...